Product details:

ISBN13:9780443217982
ISBN10:044321798X
Binding:Paperback
No. of pages:194 pages
Size:229x152 mm
Weight:450 g
Language:English
699
Category:

The Evolution of Immunotherapy Against Tumors

An Historical Approach
 
Publisher: Academic Press
Date of Publication:
 
Normal price:

Publisher's listprice:
EUR 162.00
Estimated price in HUF:
66 849 HUF (63 666 HUF + 5% VAT)
Why estimated?
 
Your price:

60 164 (57 299 HUF + 5% VAT )
discount is: 10% (approx 6 685 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
 
Availability:

 
  Piece(s)

 
Long description:

The Evolution of Immunotherapy Against Tumors: An Historical Approach summarizes the literature concerning the development of the theory of immune surveillance against tumors. It discusses the evidence for and against this theory, along with the concept of immunoediting. Finally, current approaches in anti-tumor immunotherapy will be analyzed. The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system. This indicates that tumor cells can escape immune surveillance.




  • Covers the experimental approaches to investigate immunotherapy against tumors
  • Provides a comprehensive overview of the pharmacological tools in this field
  • Serves as a reference book to researchers in the respective fields and related disciplines
Table of Contents:

Immunosurveillance against tumors Immunoediting Basic immunotherapy with IL-2 Adoptive T cell therapy DNA vaccines Dendritic cell (DC) vaccines Antibody therapy Co-applying anti-angiogenic and immune checkpoints inhibitors Conclusions